What is RAJAF?
engages in the cultivation and sale of Chinese rare medicinal herb, taiwanofungus raw material, and finished products in China.
RAJAF · Verdict
Limited reward · elevated risk
RAJAF's standout is volatility; balance sheet and profitability weigh on the picture.
Based on 88% data coverage
RAJAF · Verdict
Above average
Current ratio 0.12
-18% net margin · 0% ROE
Earnings -22.8% CAGR
-3% free-cash-flow margin
Below average
Model-based scoring. For information only — not financial advice.
engages in the cultivation and sale of Chinese rare medicinal herb, taiwanofungus raw material, and finished products in China. The company offers Taiwanofungus Oral pill, a pill form dietary supplement; Taiwanofungus Double A Oral shot, TAIWANOFUNGUS x SALVIA MILTIORRHIZA ORAL Shot, and Collagen Max Drink, a liquid form dietary supplement; and Barbie Coco, a chocolate product. The company is listed on the OTCQB in USA, operating in the Consumer Defensive sector, with a market capitalisation of 1.02B.
The scoring profile indicates weak reward characteristics across most factors, including momentum and size. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.